Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Efficacy and Safety Study of JYP0061 Tablets in Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial

NCT06158490 is registered in ClinicalTrials.gov with Guangzhou JOYO Pharma Co., Ltd as lead sponsor.

NCT NCT06158490
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06158490 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Efficacy and Safety Study of JYP0061 Tablets in Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial
Lead sponsor
Guangzhou JOYO Pharma Co., Ltd
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
December 27, 2023
Completion date
October 10, 2026
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

moderate-to-severe atopic dermatitis